TrophiPatch is an innovative allogeneic cell-based skin patch designed to promote superior wound healing by restoring a functional vascular network in damaged tissue.

The loss of a functional vasculature is a key factor underlying chronic wounds. Without sufficient blood supply, tissues cannot receive the oxygen and nutrients required for effective and timely healing.

TrophiPatch contains adipose-derived stem cells (ASCs) obtained from the fat tissue of healthy donors, embedded within an active supporting matrix. These cells naturally secrete a range of angiogenic and regenerative growth factors that stimulate the patient’s own repair processes and promote the formation of new blood vessels within the wound.

Using HekeTiss’ proprietary technology, ASCs cultured within the TrophiPatch matrix acquire enhanced angiogenic and regenerative activity, further increasing their ability to restore local vascularization and support tissue regeneration. 

TrophiPatch is the result of more than six years of research and has successfully completed preclinical testing demonstrating safety and therapeutic potential. HekeTiss has now initiated a Phase I/IIa clinical trial in collaboration with the Dermatology Division of the Geneva University Hospitals (HUG) to evaluate the safety and clinical efficacy of this regenerative therapy in patients with chronic wounds (ClinicalTrials.gov Identifier: NCT07048054).